Uniunea Europeană - română - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Uniunea Europeană - română - EMA (European Medicines Agency)

retrophin europe ltd - acidul cholic - metabolismul, erorile înnăscute - terapia cu bila și cu ficatul - acid colic fgk este indicat pentru tratamentul de erori innascute de primar sinteza acizilor biliari, de la sugari la vârsta de o lună continuă pe tot parcursul vieții tratament prin maturitate, care să cuprindă următoarele singură enzimă defecte:sterol 27-hidroxilaza (prezentarea ca cerebrotendinous xanthomatosis, ctx) deficiență;2- (sau alfa-) methylacyl-coa racemase (amacr) deficiență;colesterol 7-alfa-hidroxilaza (cyp7a1) deficit.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc aktapa ortopedica srl -

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc aktapa ortopedica srl -

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

balkan pharmaceuticals srl, sc - finasteridum - comprimate - 5 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - fibrinogenul uman, trombina umană - hemostază, chirurgicală - hemostatice - tratament suportiv în cazul în care tehnicile chirurgicale standard nu sunt suficiente pentru ameliorarea hemostazei. raplixa trebuie să fie utilizate în combinație cu aprobarea unui burete de gelatină. raplixa este indicat la adulți cu vârsta peste 18 ani.

Uniunea Europeană - română - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

srl zoofarmagro - acitat etilic - animalele nedestinate consumului Умань (în afară де pisici)

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

przedsiebiorstwo produkcji farmaceutycznej hasco-lek s.a. - naproxenum - comprimate - 500 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

przedsiebiorstwo produkcji farmaceutycznej hasco-lek s.a. - naproxenum - comprimate - 250 mg